Will Johnson & Johnson (JNJ) Q2 Innovation Medicine revenue be above $16.35B?

Track live probability, outcome prices, volume, liquidity, and resolution details for Will Johnson & Johnson (JNJ) Q2 Innovation Medicine revenue be above $16.35B?. The market currently shows a live probability of 50%, $1.1K in 24h volume, and $3.9K in liquidity.

Track live finance prediction markets focused on interest rates, inflation, stock market events, central bank decisions, and global financial forecasting trends.

This market is currently listed with an end date of Jul 15, 2026. Market timelines can change if the underlying event is postponed, rescheduled, or resolved early.

This market will resolve to "Yes" if Johnson & Johnson's Innovative Medicine revenue for the upcoming second fiscal quarter, as reported in its official company earnings materials, is above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is Johnson & Johnson's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.